Travere Therapeutics, Inc. (TVTX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Travere Therapeutics’s revenue went from $134M in fiscal 2016 to $491M in fiscal 2025, growth of about 15.6% a year.
Net income in fiscal 2025 was -$26M, a net margin of -5.2%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $651M and net income -$122M.
The diluted share count rose 133% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $651M | $491M | $233M | $145M | $109M | $132M | $198M | $175M | $164M | $155M | $134M |
| Gross profit | $641M | $480M | $225M | $134M | $105M | $128M | $192M | $170M | $159M | $151M | $129M |
| Operating income | -$133M | -$63M | -$324M | -$388M | -$320M | -$199M | -$176M | -$137M | -$80M | -$54M | -$58M |
| Net income | -$122M | -$26M | -$322M | -$111M | -$278M | -$180M | -$169M | -$146M | -$103M | -$60M | -$48M |
| EPS (diluted) | $-1.29 | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 | $-3.46 | $-2.54 | $-1.54 | $-1.29 |
| R&D | $246M | $206M | $217M | $245M | $8M | $201M | $132M | $141M | $124M | $78M | $71M |
| Revenue growth | — | +110.5% | +60.6% | +32.7% | −17.0% | −33.5% | +13.1% | +6.8% | +6.0% | +16.0% | +33.7% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $177M | $38M | -$237M | -$280M | -$186M | -$15M | -$43M | -$58M | -$25M | $7M | -$3M |
| Capital spending | -$204M | — | — | -$668000 | -$191000 | -$5M | -$7M | -$195000 | -$727000 | -$887000 | -$1M |
| Free cash flow | -$27M | — | — | -$281M | -$186M | -$20M | -$50M | -$58M | -$26M | $7M | -$5M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | $0 |
| Stock-based pay | $73M | $45M | $37M | $44M | $38M | $30M | $24M | $21M | $20M | $27M | $29M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $238M | $59M | $307M | $347M | $428M | $357M | $272M | $311M | $223M | $41M |
| Debt | — | $329M | $333M | $405M | $407M | $262M | $244M | $215M | $206M | $45M | $44M |
| Equity | — | $115M | $59M | $201M | $43M | $302M | $211M | $221M | $318M | $293M | $308M |
| Total assets | — | $605M | $594M | $789M | $673M | $777M | $607M | $605M | $709M | $520M | $525M |
| Shares (diluted) | 95M | 89M | 79M | 74M | 64M | 60M | 48M | 42M | 40M | 39M | 38M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 98.5% | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | 96.9% | 97.0% | 96.6% | 97.7% | 96.6% |
| Operating margin | -20.5% | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% | -88.8% | -78.3% | -48.7% | -34.7% | -43.6% |
| Net margin | -18.7% | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | -85.4% | -83.5% | -62.5% | -38.6% | -35.9% |
| FCF margin | -4.2% | — | — | -193.3% | -170.4% | -15.1% | -25.0% | -33.3% | -15.6% | 4.2% | -3.6% |
| ROIC | — | -11.2% | -65.3% | -50.6% | -56.1% | -27.9% | -34.7% | -31.5% | -12.0% | -12.6% | -13.8% |
| ROE | — | -22.2% | -544.3% | -55.5% | -649.9% | -59.6% | -80.2% | -66.2% | -32.3% | -20.4% | -15.6% |
Frequently asked questions
What is Travere Therapeutics’s annual revenue?
$491M in fiscal 2025 and $651M over the twelve months to September 30, 2026.
How much profit does Travere Therapeutics make?
Net income was -$26M in fiscal 2025 (net margin -5.2%).
Is Travere Therapeutics’s revenue growing?
Yes: revenue rose 110.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.